Anupam Rama
Stock Analyst at JP Morgan
(4.40)
# 350
Out of 5,122 analysts
310
Total ratings
50%
Success rate
20.46%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $179 → $177 | $138.98 | +27.36% | 20 | Jan 12, 2026 | |
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $44.67 | +114.91% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $37.28 | +79.72% | 9 | Dec 19, 2025 | |
| VOR Vor Biopharma | Maintains: Overweight | $43 → $40 | $12.82 | +212.01% | 2 | Dec 19, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $147 → $145 | $107.21 | +35.25% | 7 | Dec 19, 2025 | |
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $8.37 | -28.32% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $11.00 | +81.82% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $26.14 | +22.42% | 6 | Nov 18, 2025 | |
| ENTA Enanta Pharmaceuticals | Initiates: Overweight | $17 | $13.57 | +25.28% | 1 | Nov 14, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $40 → $33 | $21.25 | +55.29% | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $57 | $57.75 | -1.30% | 10 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $11.16 | +141.94% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $77 | $78.18 | -1.51% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.28 | +33.05% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $6.54 | +68.20% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $23.32 | +54.37% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $24.03 | -0.12% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $34.23 | +130.79% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $7.38 | +49.05% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $47.97 | -22.87% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.60 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $20.28 | +18.34% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $51.21 | +56.22% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $24.80 | +371.77% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $16.43 | +210.41% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $32.84 | +33.98% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $44.96 | -11.03% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.03 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.63 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $6.07 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.48 | +100.62% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $5.70 | +1,478.95% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $5.04 | +4,860.32% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.99 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $64.73 | -10.40% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $19.99 | -39.97% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $7.68 | +381.77% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $85.59 | -35.74% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.32 | +268.22% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $10.59 | +164.53% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.93 | +93.34% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.19 | +23,709.52% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.96 | +42.41% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $351.80 | -61.06% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $11.33 | +323.65% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.48 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.88 | +3,309.09% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $74.83 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.79 | - | 2 | Jul 21, 2017 |
Neurocrine Biosciences
Jan 12, 2026
Maintains: Overweight
Price Target: $179 → $177
Current: $138.98
Upside: +27.36%
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $44.67
Upside: +114.91%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $37.28
Upside: +79.72%
Vor Biopharma
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $12.82
Upside: +212.01%
Nuvalent
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $107.21
Upside: +35.25%
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $8.37
Upside: -28.32%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $11.00
Upside: +81.82%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $26.14
Upside: +22.42%
Enanta Pharmaceuticals
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.57
Upside: +25.28%
Syndax Pharmaceuticals
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $21.25
Upside: +55.29%
Nov 12, 2025
Maintains: Overweight
Price Target: $55 → $57
Current: $57.75
Upside: -1.30%
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $11.16
Upside: +141.94%
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $78.18
Upside: -1.51%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.28
Upside: +33.05%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $6.54
Upside: +68.20%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $23.32
Upside: +54.37%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $24.03
Upside: -0.12%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $34.23
Upside: +130.79%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $7.38
Upside: +49.05%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $47.97
Upside: -22.87%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.60
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $20.28
Upside: +18.34%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $51.21
Upside: +56.22%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $24.80
Upside: +371.77%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $16.43
Upside: +210.41%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $32.84
Upside: +33.98%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $44.96
Upside: -11.03%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.03
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.63
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $6.07
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.48
Upside: +100.62%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $5.70
Upside: +1,478.95%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $5.04
Upside: +4,860.32%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $10.99
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $64.73
Upside: -10.40%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $19.99
Upside: -39.97%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $7.68
Upside: +381.77%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $85.59
Upside: -35.74%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.32
Upside: +268.22%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $10.59
Upside: +164.53%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.93
Upside: +93.34%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.19
Upside: +23,709.52%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $18.96
Upside: +42.41%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $351.80
Upside: -61.06%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $11.33
Upside: +323.65%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $15.48
Upside: -
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.88
Upside: +3,309.09%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $74.83
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.79
Upside: -